Text size A A

News

Date Title and Summary Additional Formats
Toggle Summary AGTC to Participate in Upcoming Investor Conferences
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Aug. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and potential commercialization of adeno-associated virus (AAV)-based gene
View HTML
Toggle Summary AGTC Receives Positive Type C Meeting Feedback from the FDA for the Company’s Design and Operating Procedures of its Planned cGMP Manufacturing Facility
— FDA feedback marks a key milestone in the construction of the facility expected to support AGTC’s pipeline, including the late-stage development and potential commercialization of AGTC’s X-Linked Retinitis Pigmentosa (XLRP) and Achromatopsia B3 (ACHMB3) programs — GAINESVILLE, Fla.
View HTML
Toggle Summary AGTC Announces Pricing of $10 Million Underwritten Public Offering
GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , July 12, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene
View HTML
Toggle Summary AGTC Announces Proposed Underwritten Public Offering
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , July 12, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies
View HTML
Toggle Summary AGTC to Present at Upcoming American Society of Retina Specialists Annual Meeting
July 7, 2022 at 8:00 AM EDT GAINESVILLE, Fla. , and CAMBRIDGE, Mass., July 07, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment
View HTML
Toggle Summary AGTC Announces Key Appointments to Leadership Team
AGTC Welcomes Eduardo Jacobo as the Sr. Vice President of GMP Manufacturing and Dr. David Jacobs as the Sr. Vice President of Clinical Research and Medical Affairs GAINESVILLE, Fla. and CAMBRIDGE, Mass., June 08, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a
View HTML
Toggle Summary AGTC to Present Three-Month Interim Results from the SKYLINE Clinical Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa at the 45th Macula Society Annual Meeting
GAINESVILLE, Fla. , and CAMBRIDGE, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating
View HTML
Toggle Summary AGTC Announces Age-Related Macular Degeneration Scientific Advisory Board
GAINESVILLE, Fla. , and CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating
View HTML
Toggle Summary AGTC to Present at the H.C. Wainwright Global Investment Conference
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , May 18, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating
View HTML
Toggle Summary AGTC Announces Positive Three-Month Interim Results from Skyline Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa
– 62.5% of Patients in Dose Group B Were Responders for Improvements in Visual Sensitivity, the Study’s Primary Efficacy Endpoint – – Continued Strong Safety Data – – Robust Safety and Efficacy Data Consistent with Previously Reported Results from the Phase 1/2 Trial in XLRP – – Company to Host
View HTML
Visionary science for life changing cures.